Streptococcus Pyogenes
US-FDASourced from openFDA
GET
/api/v1/drug/streptococcus-pyogenesIndications
Sourced from openFDA- Rx Only*
Dosage & administration
Sourced from openFDAAdults and children: At the onset of symptoms, dissolve 5 pellets under the tongue 3 times a day until symptoms are relieved or as directed by a doctor.
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
488 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Diarrhoea336.8%
- 2Pain336.8%
- 3Headache306.1%
- 4Fatigue295.9%
- 5Nausea275.5%
- 6Arthralgia265.3%
- 7Dizziness255.1%
- 8Pain In Extremity214.3%
- 9Asthenia183.7%
- 10Abdominal Pain Upper173.5%
- 11Eye Pain173.5%
- 12Fall173.5%
- 13Gait Disturbance173.5%
- 14Muscle Spasms173.5%
- 15Dyspnoea163.3%
Literature
Recent PubMed references pinned to Streptococcus Pyogenes as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Mechanisms underlying pyogenic bacterial infections of the skin.Archives of microbiology · 2026 · Huang C, Yan X, Xu X, et al.PMID 42249917DOI 10.1007/s00203-026-04987-3
- Whole Genome Sequencing Analysis of Group A Streptococcus Isolates From Pediatric Patients in Korea From 2013 to 2024.Journal of Korean medical science · 2026 · An S, Kim SJ, Shin JH, et al.PMID 42237174DOI 10.3346/jkms.2026.41.e158
- Group A Streptococcus Disease Outbreak Associated with Large Congregate Shelter, Chicago, Illinois, USA, October 2023-January 2024.Emerging infectious diseases · 2026 · Toews KA, Tietje L, Meyers A, et al.PMID 42230280DOI 10.3201/eid3206.250726
- AcrIIA8 is a putative phage structural protein of the HTJ2 family that does not inhibit Streptococcus pyogenes Cas9.Protein science : a publication of the Protein Society · 2026 · An SY, Kim I, Hong SH, et al.PMID 42223080DOI 10.1002/pro.70651
- Invasive group A Streptococcal infections in Franche-Comté, France (2022-2023).European journal of dermatology : EJD · 2026 · Dias J, Patry I, Moreau J, et al.PMID 42183688DOI 10.1684/ejd.2026.5058
- Identification of immunostimulatory antigens in Group A Streptococcus-derived vesicles.Proceedings of the National Academy of Sciences of the United States of America · 2026 · Gaytán MO, Dookie RS, Chakraborty S, et al.PMID 42118829DOI 10.1073/pnas.2537351123
- Comparative evaluation of performance and precision of multiplex immunoassays measuring human IgG to Streptococcus pyogenes vaccine antigens.Frontiers in immunology · 2026 · Morici M, Gilmour J, Rossi O, et al.PMID 42112352DOI 10.3389/fimmu.2026.1810546
- The sweet truth about germinal centers.Trends in immunology · 2026 · Rao VN, Silva ALT, Coelho CH, et al.PMID 42091410DOI 10.1016/j.it.2026.04.005
Clinical trials
The 10 most recently updated of 89 ClinicalTrials.gov registrations naming Streptococcus Pyogenes as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract IllnessCompleted · Phase 2 · Interventional · 822 enrolled · University of ArizonaNCT02148796updated 2026-06-02
- A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young AdultsNot yet recruiting · Phase 1 · Interventional · 80 enrolled · Vaxcyte, Inc.NCT07616934updated 2026-06-01
- Prophylactic Effect of Probiotic Streptococcus Salivarius eK12 Against Recurrent Streptococcus Pyogenes Pharyngotonsillitis Infection in PediatricsActive not recruiting · Interventional · 82 enrolled · Liaquat University of Medical & Health SciencesNCT06370208updated 2026-05-28
- Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of AgeRecruiting · Phase 2 · Interventional · 38 enrolled · Protara TherapeuticsNCT05871970updated 2026-05-18
- Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder CancerRecruiting · Phase 2 · Interventional · 131 enrolled · Protara TherapeuticsNCT05951179updated 2026-05-18
- Impact of a Daily Application of an Omega-3 Monoglycerides Based Serum and Cream on the Skin MicrobiotaNot yet recruiting · Interventional · 10 enrolled · SCF PharmaNCT07583121updated 2026-05-13
- Group A Streptococcus Saliva StudyActive not recruiting · Interventional · 200 enrolled · The Hospital for Sick ChildrenNCT06473506updated 2026-05-07
- Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference CohortsCompleted · Phase 3 · Interventional · 113 enrolled · Hansa Biopharma ABNCT05369975updated 2026-05-05
- Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney TxCompleted · Phase 3 · Interventional · 64 enrolled · Hansa Biopharma ABNCT04935177updated 2026-04-30
- A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient GroupRecruiting · Phase 3 · Interventional · 150 enrolled · Hansa Biopharma ABNCT05937750updated 2026-04-24
Frequently asked questions
- What is Streptococcus Pyogenes used for?
- According to FDA labeling, Streptococcus Pyogenes carries indications including: Rx Only*. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
Note. Data for
streptococcus-pyogenes is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.